CD47 and neoplasm: When combining two different mechanisms of action, i.e., inhibition of CD47 and re-targeting of T-cells to the tumor, equivalent activity of NILK-2401 plus NILK-2301 therapy at >600-fold (LS174T) to >3,000-fold (MKN-45) lower doses compared to NILK-2301 monotherapy was observed, i.e., ≈0.02 vs. 13.3 and, ≈0.03 vs. 100 nM, respectively.